{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T17:26:17Z","timestamp":1789320377522,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25293088"],"award-info":[{"award-number":["25293088"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","award":["25293088"],"award-info":[{"award-number":["25293088"]}],"id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.humpath.2017.07.001","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T08:59:50Z","timestamp":1499936390000},"page":"60-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Alteration of PDGFR\u03b2-Akt-mTOR pathway signaling in fibrosarcomatous transformation of dermatofibrosarcoma protuberans"],"prefix":"10.1016","volume":"67","author":[{"given":"Yuka","family":"Hiraki-Hotokebuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Kohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nokitaka","family":"Setsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuma","family":"Yuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihide","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masutaka","family":"Furue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2017.07.001_bb0005","series-title":"World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone","first-page":"77","article-title":"Dermatofibrosarcoma protuberans","author":"Fletcher","year":"2013"},{"key":"10.1016\/j.humpath.2017.07.001_bb0010","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jaad.2010.06.020","article-title":"Dermatofibrosarcoma protuberans a clinicopathological immunohistochemical genetic (COL1A1-PDGFB) and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors","volume":"65","author":"Llombart","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.humpath.2017.07.001_bb0015","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1158\/1078-0432.CCR-13-1411","article-title":"Neo-adjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase-II DeCOG trial with long-term follow-up","volume":"20","author":"Ugurel","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2017.07.001_bb0020","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1158\/1078-0432.CCR-09-3401","article-title":"Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients","volume":"16","author":"Kerob","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2017.07.001_bb0025","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1200\/JCO.2009.25.7899","article-title":"Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials","volume":"28","author":"Rutkowski","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2017.07.001_bb0030","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.tibs.2006.04.003","article-title":"Ribosomal protein S6 phosphorylation: from protein synthesis to cell size","volume":"31","author":"Ruvinsky","year":"2006","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.humpath.2017.07.001_bb0035","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/sj.onc.1201990","article-title":"Translational induction of the c-myc oncogene via activation of the FRAP\/TOR signalling pathway","volume":"17","author":"West","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2017.07.001_bb0040","doi-asserted-by":"crossref","first-page":"23679","DOI":"10.1074\/jbc.M700563200","article-title":"The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells","volume":"282","author":"Dormond","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.humpath.2017.07.001_bb0045","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/modpathol.2009.104","article-title":"EGFR-dependent and independent activation of Akt\/mTOR cascade in bone and soft tissue tumors","volume":"22","author":"Dobashi","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2017.07.001_bb0050","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/cncr.28506","article-title":"Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors","volume":"120","author":"Yamada","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2017.07.001_bb0055","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1158\/1078-0432.CCR-12-1067","article-title":"Prognostic significance of AKT\/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors","volume":"19","author":"Endo","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2017.07.001_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068985","article-title":"Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS\/WT1), Ewing's sarcoma (EWS\/FLI1) and Wilms' tumor (WT1)","volume":"8","author":"Subbiah","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.humpath.2017.07.001_bb0065","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.ajpath.2013.01.002","article-title":"Novel dedifferentiated liposarcoma xenograft models reveal PTEN down-regulation as a malignant signature and response to PI3K pathway inhibition","volume":"182","author":"Smith","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.humpath.2017.07.001_bb0070","first-page":"3719","article-title":"The dermatofibrosarcoma protuberans-associated collagen type Ialpha1\/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB","volume":"59","author":"Shimizu","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2017.07.001_bb0075","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/PAS.0b013e3181cf7fc1","article-title":"Dermatofibrosarcoma protuberans of the vulva: a clinicopathologic and immunohistochemical study of 13 cases","volume":"34","author":"Edelweiss","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2017.07.001_bb0080","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/ijc.25826","article-title":"Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib","volume":"129","author":"Stacchiotti","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.humpath.2017.07.001_bb0085","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1038\/sj.onc.1204426","article-title":"Structural and functional analysis of a chimeric protein COLIA1-PDGFB generated by the translocation t(17;22)(q22;q13.1) in dermatofibrosarcoma protuberans (DP)","volume":"20","author":"Simon","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2017.07.001_bb0090","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1365-2559.2007.02868.x","article-title":"Platelet-derived growth factor receptors and ligands are up-regulated in paediatric fibromatoses","volume":"51","author":"Gibson","year":"2007","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2017.07.001_bb0095","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1172\/JCI28984","article-title":"PDGFRs are critical for PI3K\/Akt activation and negatively regulated by mTOR","volume":"117","author":"Zhang","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.humpath.2017.07.001_bb0100","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1524-4725.2011.02292.x","article-title":"Dermatofibrosarcoma protuberans: a review of the literature","volume":"38","author":"Bogucki","year":"2012","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.humpath.2017.07.001_bb0105","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1200\/JCO.2002.01.027","article-title":"Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans","volume":"20","author":"Rubin","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2017.07.001_bb0110","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1200\/JCO.2005.07.088","article-title":"Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225","volume":"23","author":"McArthur","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2017.07.001_bb0115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1477-7819-11-59","article-title":"Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by imatinib","volume":"11","author":"Wicherts","year":"2013","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.humpath.2017.07.001_bb0120","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/1346-8138.12080","article-title":"Successful treatment of unresectable dermatofibrosarcoma protuberans on finger with imatinib mesylate and Mohs microsurgery","volume":"40","author":"Jeon","year":"2013","journal-title":"J Dermatol"},{"key":"10.1016\/j.humpath.2017.07.001_bb0125","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.humpath.2003.09.016","article-title":"Microsatellite instability and p53 mutation associated with tumor progression in dermatofibrosarcoma protuberans","volume":"35","author":"Takahira","year":"2004","journal-title":"Hum Pathol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817717302411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817717302411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T23:13:11Z","timestamp":1617837191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817717302411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":25,"alternative-id":["S0046817717302411"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2017.07.001","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alteration of PDGFR\u03b2-Akt-mTOR pathway signaling in fibrosarcomatous transformation of dermatofibrosarcoma protuberans","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2017.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}